Research is underway for an experimental treatment for patients with succinate dehydrogenase (SDH) deficient gastrointestinal ...

Largest prospective clinical trial to-date in a rare subtype of GISTROCKVILLE, Md. and SUZHOU, China, (GLOBE NEWSWIRE) -- ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.

This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...

GIST stands for gastrointestinal stromal tumor. When tumors spread from the gastrointestinal (GI) tract to distant tissues or organs, it is called a metastatic GIST. Newer therapies, such as imatinib ...

Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...

Gastrointestinal stroma tumors (GIST) are cancers that start in specialized nerve cells found in the digestive system, from the esophagus and stomach to the intestines and rectum. They are rare, but ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w558df/gastrointestinal) has announced the addition of the "Gastrointestinal ...

Cogent Biosciences Inc. (NASDAQ:COGT) is among the hottest SMID-cap stocks so far in 2025. On November 13, H.C. Wainwright ...

Long-term survival (over 10 years) of inoperable/metastatic GISTs: A retrospective series of 141 patients (pts) of the french sarcoma group (FSG). This is an ASCO Meeting Abstract from the 2017 ASCO ...

Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib. Background: GIST of ...